DYOR! (Comments?)

Arjen in shares mag this week there is a full 2-3 page article on all the bios, prm, pro, azm, acambis, oxford bio etc are all featured, good place to start your research for 2.5

good luck

I suppose I better open my Shares mag..............

I am a big fan of this company and have been in since the 30p days topping up on weakness.

Hope this helps on your research it is the Teather and Greenwood note on this company from last month. It explains it pretty well although I think the fair value they put on it is somewhat conservative

Optimum time to invest in key proteomics play
We believe it is now the optimum time to buy into Proteome as its risk
profile has been reduced by the validation of its technologies by key
partners. Furthermore, the vast majority of programmes have yet to be
partnered, providing significant near-term upside to the stock. We
ascribe a net present value to Proteome of 247p per share providing
substantial upside to the current price. We expect further upside to be
achievable as early stage programmes move towards partnering and
commercialisation.

__ Investment profile -Proteome is a leading pure play proteomics company
performing drug target and biomarker development. Rather than looking to take a
portfolio approach in gaining exposure to the field of proteomics, due to lack of companies in this field we suggest buying into Proteome alone. Its range of
technologies and programmes provides an investment that gives exposure to
proteomics biomarkers, drug development and proteomics reagents and
technologies. The range of technologies and programmes possessed by Proteome
also reduces exposure to the risk of product failure through a decreased reliance on individual products.

__ Validated technology and strong news flow -Proteomes technology has
already been validated by the industry with the announcement of the licensing of
biomarkers to two leading diagnostics players over the last 12 months. We expect
diagnostic tests using these biomarkers to be launched by the partners in 2004. A wealth of further licensing agreements are likely to be signed for the
commercialisation of other biomarkers against additional diseases that have either been identified or will be identified in the future. Further deals are also likely to result from research alliances with pharmaceutical and biotechnology companies looking to develop therapeutics against novel targets that Proteome is capable of identifying and characterising.

__ Near-term profitability -We forecast that Proteome is currently on the cusp of moving into profit, which combined with the current cash position, will allow
Proteome to be self-funding going forward. This should result in there being little prospect of future dilution for current investors, unlike many other investments in this sector which will need further fundraisings.

__ Significant upside -Our current NPV model for Proteome suggests a fair value
of 247p per share for the stock. This is a significant premium to the current price and provides the prospect of substantial upside to investors as future
developments drive the price of the stock towards our perceived fair value. The
companys late stage pipeline accounts for the vast majority of the value. We
believe there is a low risk of failure to reach market for the late stage programmes and therefore believe there is little developmental risk to our valuation. In addition, as earlier stage products advance, the increase in size of the portfolio will further spread the risk of individual developmental product failure

If you seriously want to know anything about PRM, I strongly suggest you read the PRM BB on ADVFN. Some useful links in the header and a history of very informative posts from a plethora of very well respected posters. I particularly recommend reading posts from jt, Tuco, Steverob, Maxwellsdemon, Goatherd, Fandango, Square1 and others to whom I apologise for not remembering off the top of my head.

Thanks to all for taking the time to give such good info.
It seems - on first impressions - to have a lot of potential.aj

I put the two day chart on this thread, because I'm an investor who likes to trade. And this is a share which is currently giving that opportunity!

Amazingly good news today I topped up on the news

RNS Number:9656R
Proteome Sciences PLC
12 November 2003



PROTEOME SCIENCES plc

PRESS RELEASE


Proteome Sciences Awarded Grant of US Patent For Diagnosis of Three Major
Cancers

Proteome Sciences plc ("Proteome Sciences"), is pleased to announce that it has
today been granted US Patent No. 6,645,465 entitled "Annexin Proteins and
Autoantibodies as Serum Markers for Cancer".

Annexins are a class of at least 12 different proteins with a putative role in
controlling cell signalling and metabolism. Elevation of certain annexins
correlates with various diseases. Work funded by Proteome Sciences led to the
discovery that anexins I and II are elevated in three major cancers, namely
lung, breast and oesophageal cancers. Significantly, it was possible to develop
a test that could detect antibodies to these proteins in the blood of patients
with tumours, but not in healthy individuals.

The granted patent includes claims to the use of annexins and antibodies to them
in the diagnosis of lung, breast and oesophageal cancers, which collectively
account for an estimated 400,000 new cases each year in the US, roughly 1
million worldwide. Proteome Sciences is actively pursuing partners to co-develop
new diagnostic and prognostic tests based on detection of annexin
autoantibodies, in line with its long-standing practice of partnering
activities.

Commenting on the announcement, Christopher Pearce, Chief Executive of Proteome
Sciences said :

"We are very pleased to see the grant of a key patent for an important class of
cancer biomarkers. This is the first of a series of patents to be granted from
our research in cancer and which underpins the value of our early programmes in
biomarker discovery. This allows us to secure strong commercial partnerships to
develop new diagnostic and prognostic assays for these important diseases where
diagnosis is often made too late for effective treatment and to accelerate the
development of therapeutic targets.


Using its ProteoSHOPTM tool box Proteome Sciences is focused to discover and
validate new biomarkers across a broad range of major diseases including
neurodegeneration, neuroscience, diabetes/obesity, cardiovascular disease and
cancer, which, together with its strong portfolio of existing intellectual
property, places us at the forefront of applied proteomics.".


- Ends -

Notice GNI topped up to the tune 1.3M shares on Friday/last week, that's confidence.

A :- Result of E.G.M.

B :- Dr G.W.Schmidt resigned ------------- Frankfurt facilities.

Agreement with Medical Research Council

Appears - to me - to be Very Positive to the extent I think everyone on the
tread should read it rgds aj

Directors Interest:-

Dr Sandra S.Steiner

Looks like this has started moving up again.

I am amazed there is such a lack of interest/few posts on this share as it is
a very interesting one.aj

Today + 1.00 / + 0 .51 per cent

No, I'm very interested and have posted such on numerous occassions!

Meant to post this while back. Its a good profile on PRM.

http://www.pharmaco-genomics.co.uk/admin/files/PGS040515.pdf

Has PRM peaked? Or has it further to go?

IMHO this has a lot further to run, credit lyonais upped it's stake this week and the directors have bought big style, also changed advisor, I think this is still early days and I'm adding more.

Dam dam dam, missed it, should of bought last night, thought it woul push down one last time, still I think will move to new highs 3 target or q1.

Mmmmhhhh - wondered whether to post as most investors hate to hear about negatives. So just a couple of thoughts in summary and dyor.

1. Check out the fundamentals - valuation vs sales vs future potential royalty income stream.

2. Primarily a diagnostics test development Company - check out the biggest diagnostic players/their turnovers/profits etc. To give you a start - look at Roche/Abbot and Axis Shield platforms/products and how they are sold. Whose platforms will PRM's tests go on to and what is average take? Plus latest in-vitro, simple urine/blood tests cost less than 3c per strip to produce. Work out the quantity of tests/likely royalty income stream should the strips replace some of the more complex assay test platforms used in labs. Did you know there are already simple blood test strips for detecting cancer? Further tests are then done to determine the specific type/location.

3. Why are PRM's diagnostic markers better than existing/others also being developed? At the end of the day the cost of the test/accuracy will determine sales/income levels. Also approval FDA/EU for in-vitro diagnostic systems are simple/fast compared to treatments/drug testing so lead time/patent benefits very limited. Generic/copying with marginally different assays/procedures a problem in diagnostic testing.

4. PRM has been hyped tremendously and often last pump before the decline (end of the push) is takeover rumours which have now surfaced.

In summary this Company is valued at some 250m - work out the number of tests that need to be sold and future royalty income stream to back up this valuation.

Having said all the above I should point out I bought in at under 40p and sold far too early so wtfdik and this could still go to 250 or higher. No position currently.

Good luck everyone.

Suggest today's rise is as a result of Shares making it one of their tips for 2004 (p22).